| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |